BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

598 related articles for article (PubMed ID: 28675654)

  • 1. Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer.
    Malgerud L; Lindberg J; Wirta V; Gustafsson-Liljefors M; Karimi M; Moro CF; Stecker K; Picker A; Huelsewig C; Stein M; Bohnert R; Del Chiaro M; Haas SL; Heuchel RL; Permert J; Maeurer MJ; Brock S; Verbeke CS; Engstrand L; Jackson DB; Grönberg H; Löhr JM
    Mol Oncol; 2017 Oct; 11(10):1413-1429. PubMed ID: 28675654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Utility of Circulating Tumor DNA for Molecular Assessment and Precision Medicine in Pancreatic Cancer.
    Takai E; Totoki Y; Nakamura H; Kato M; Shibata T; Yachida S
    Adv Exp Med Biol; 2016; 924():13-17. PubMed ID: 27753011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
    Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
    J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of KRAS and SMAD4 mutations in formalin-fixed paraffin-embedded tissues as a biomarker for pancreatic cancer.
    Yokose T; Kitago M; Matsuda S; Sasaki Y; Masugi Y; Nakamura Y; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Yusuke F; Nakano Y; Endo Y; Abe K; Tokino T; Kitagawa Y
    Cancer Sci; 2020 Jun; 111(6):2174-2182. PubMed ID: 32314446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variant Profiling of Candidate Genes in Pancreatic Ductal Adenocarcinoma.
    Huang J; Löhr JM; Nilsson M; Segersvärd R; Matsson H; Verbeke C; Heuchel R; Kere J; Iafrate AJ; Zheng Z; Ye W
    Clin Chem; 2015 Nov; 61(11):1408-16. PubMed ID: 26378065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of next-generation sequencing on the clinical diagnosis of pancreatic cysts.
    Jones M; Zheng Z; Wang J; Dudley J; Albanese E; Kadayifci A; Dias-Santagata D; Le L; Brugge WR; Fernandez-del Castillo C; Mino-Kenudson M; Iafrate AJ; Pitman MB
    Gastrointest Endosc; 2016 Jan; 83(1):140-8. PubMed ID: 26253016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutant
    Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
    Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutation analysis by deep sequencing of pancreatic juice from patients with pancreatic ductal adenocarcinoma.
    Choi MH; Mejlænder-Andersen E; Manueldas S; El Jellas K; Steine SJ; Tjensvoll K; Sætran HA; Knappskog S; Hoem D; Nordgård O; Hovland R; Molven A
    BMC Cancer; 2019 Jan; 19(1):11. PubMed ID: 30611220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel hotspot and rare somatic mutation p.A138V, at TP53 is associated with poor survival of pancreatic ductal and periampullary adenocarcinoma patients.
    Saha G; Singh R; Mandal A; Das S; Chattopadhyay E; Panja P; Roy P; DeSarkar N; Gulati S; Ghatak S; Ghosh S; Banerjee S; Roy B; Ghosh S; Chaudhuri D; Arora N; Biswas NK; Sikdar N
    Mol Med; 2020 Jun; 26(1):59. PubMed ID: 32552660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted next generation sequencing of endoscopic ultrasound acquired cytology from ampullary and pancreatic adenocarcinoma has the potential to aid patient stratification for optimal therapy selection.
    Gleeson FC; Kerr SE; Kipp BR; Voss JS; Minot DM; Tu ZJ; Henry MR; Graham RP; Vasmatzis G; Cheville JC; Lazaridis KN; Levy MJ
    Oncotarget; 2016 Aug; 7(34):54526-54536. PubMed ID: 27203738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Profiling of conditionally reprogrammed cell lines for in vitro chemotherapy response prediction of pancreatic cancer.
    Lee HS; Kim E; Lee J; Park SJ; Hwang HK; Park CH; Jo SY; Kang CM; Hong SM; Kang H; Jo JH; Cho IR; Chung MJ; Park JY; Park SW; Song SY; Han JM; Kim S; Bang S
    EBioMedicine; 2021 Mar; 65():103218. PubMed ID: 33639403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications.
    Hu HF; Ye Z; Qin Y; Xu XW; Yu XJ; Zhuo QF; Ji SR
    Acta Pharmacol Sin; 2021 Nov; 42(11):1725-1741. PubMed ID: 33574569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive Analysis of Somatic Mutations in Driver Genes of Resected Pancreatic Ductal Adenocarcinoma Reveals KRAS G12D and Mutant TP53 Combination as an Independent Predictor of Clinical Outcome.
    Shoucair S; Habib JR; Pu N; Kinny-Köster B; van Ooston AF; Javed AA; Lafaro KJ; He J; Wolfgang CL; Yu J
    Ann Surg Oncol; 2022 Apr; 29(4):2720-2731. PubMed ID: 34792696
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Sinn M; Sinn BV; Treue D; Keilholz U; Damm F; Schmuck R; Lohneis P; Klauschen F; Striefler JK; Bahra M; Bläker H; Bischoff S; Pelzer U; Oettle H; Riess H; Budczies J; Denkert C
    Clin Cancer Res; 2020 Jul; 26(14):3732-3739. PubMed ID: 32234756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Next generation sequencing of pancreatic ductal adenocarcinoma: right or wrong?
    Connor AA; Gallinger S
    Expert Rev Gastroenterol Hepatol; 2017 Jul; 11(7):683-694. PubMed ID: 28460572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pancreatic adenocarcinoma with a germline PTEN p.Arg234Gln mutation.
    Uemura S; Matsubayashi H; Kiyozumi Y; Uesaka K; Yamamoto Y; Sasaki K; Abe M; Urakami K; Kusuhara M; Yamaguchi K
    Fam Cancer; 2018 Apr; 17(2):255-259. PubMed ID: 28755079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic Cancer.
    Hayashi H; Kohno T; Ueno H; Hiraoka N; Kondo S; Saito M; Shimada Y; Ichikawa H; Kato M; Shibata T; Morizane C; Sakamoto Y; Shimada K; Komatsu Y; Sakamoto N; Okusaka T
    Pancreas; 2017 Mar; 46(3):335-340. PubMed ID: 28099251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets.
    Witkiewicz AK; McMillan EA; Balaji U; Baek G; Lin WC; Mansour J; Mollaee M; Wagner KU; Koduru P; Yopp A; Choti MA; Yeo CJ; McCue P; White MA; Knudsen ES
    Nat Commun; 2015 Apr; 6():6744. PubMed ID: 25855536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pancreatic circulating tumor cell detection by targeted single-cell next-generation sequencing.
    Yu J; Gemenetzis G; Kinny-Köster B; Habib JR; Groot VP; Teinor J; Yin L; Pu N; Hasanain A; van Oosten F; Javed AA; Weiss MJ; Burkhart RA; Burns WR; Goggins M; He J; Wolfgang CL
    Cancer Lett; 2020 Nov; 493():245-253. PubMed ID: 32896616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The genetic landscape of pancreatic head ductal adenocarcinoma in China and prognosis stratification.
    Yang Y; Ding Y; Gong Y; Zhao S; Li M; Li X; Song G; Zhai B; Liu J; Shao Y; Zhu L; Pang J; Ma Y; Ou Q; Wu X; Zhang Z
    BMC Cancer; 2022 Feb; 22(1):186. PubMed ID: 35180847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.